Olix Pharmaceuticals Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Public

  • Employees
  • 67

Employees

  • Stock Symbol
  • 226950

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $56.08
  • (As of Monday Closing)

Olix Pharmaceuticals General Information

Description

OliX Pharmaceuticals Inc is a clinical stage biotechnology company. It is engaged in developing RNA interference (RNAi) technology therapeutics for dermal, ophthalmic and pulmonary diseases. The company's pipeline products include OLX101, OLX201, OLX301, OLX102, and others.

Contact Information

Formerly Known As
BMT (Biomolecular Therapeutics), Biomolecular Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 953 Daewangpangyo-ro
  • Sujeong-gu
  • Seongnam, Gyeonggi 13106
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
KRX
Vertical(s)
Corporate Office
  • 953 Daewangpangyo-ro
  • Sujeong-gu
  • Seongnam, Gyeonggi 13106
  • South Korea
+82

Olix Pharmaceuticals Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Olix Pharmaceuticals Stock Performance

As of 16-Nov-2026, Olix Pharmaceuticals’s stock price is $56.08. Its current market cap is $1.28B with 22.8M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$56.08 $60.63 $50.59 - $146.56 $1.28B 22.8M 228K -$0.39

Olix Pharmaceuticals Financials Summary

As of 30-Jun-2026, Olix Pharmaceuticals has a trailing 12-month revenue of $9.4M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 2,061,906 1,890,014 250,324 190,660
Revenue 9,396 10,306 4,161 13,052
EBITDA (8,780) (7,046) (25,078) (10,175)
Net Income (9,668) (11,062) (29,799) (14,610)
Total Assets 177,617 135,670 48,371 79,791
Total Debt 13,493 16,171 26,608 30,541
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Olix Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Olix Pharmaceuticals‘s full profile, request access.

Request a free trial

Olix Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
OliX Pharmaceuticals Inc is a clinical stage biotechnology company. It is engaged in developing RNA interference (RNAi)
Drug Discovery
Seongnam, South Korea
67 As of 2025

Macclesfield, United Kingdom
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Olix Pharmaceuticals Competitors (78)

One of Olix Pharmaceuticals’s 78 competitors is Redx Pharma, a Venture Capital-Backed company based in Macclesfield, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Redx Pharma Venture Capital-Backed Macclesfield, United Kingdom
Fate Therapeutics Formerly VC-backed San Diego, CA
Beam Therapeutics Formerly VC-backed Cambridge, MA
Immunocore Holdings Formerly VC-backed Abingdon, United Kingdom
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
You’re viewing 5 of 78 competitors. Get the full list »

Olix Pharmaceuticals Patents

Olix Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026054553-A1 Double-stranded rna for innate immune response-based anticancer therapy, and use thereof Pending 06-Sep-2024
WO-2026049536-A1 Rnai agent targeting apoc3 gene and use thereof Pending 30-Aug-2024
WO-2024210530-A1 Rnai agents targeting lpa gene and use thereof Inactive 03-Apr-2023
WO-2024186166-A1 Double-stranded rna having innate immune response-inducing effect, and use thereof Inactive 08-Mar-2023
AU-2024232235-A1 Rnai formulation for prevention or treatment of obesity and combination therapy using same Pending 08-Mar-2023 A61P3/04
To view Olix Pharmaceuticals’s complete patent history, request access »

Olix Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Olix Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Olix Pharmaceuticals‘s full profile, request access.

Request a free trial

Olix Pharmaceuticals Investments (3)

Olix Pharmaceuticals’s most recent deal was a PIPE with PCL for . The deal was made on 12-Dec-2022.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
PCL 12-Dec-2022 PIPE Other Healthcare Technology Systems
Golf Korea (957.6 Square Meters of Land Property in Seongnam, South Korea) 29-Dec-2021 Corporate Asset Purchase Buildings and Property
Sungkyunkwan University (Patent Right for Nucleic Acid Molecules Inducing RNA Interference) 30-Aug-2018 Corporate Asset Purchase Buildings and Property
To view Olix Pharmaceuticals’s complete investments history, request access »

Olix Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

39.45 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Olix Pharmaceuticals’s complete esg history, request access »

Olix Pharmaceuticals FAQs

  • When was Olix Pharmaceuticals founded?

    Olix Pharmaceuticals was founded in 2010.

  • Where is Olix Pharmaceuticals headquartered?

    Olix Pharmaceuticals is headquartered in Seongnam, South Korea.

  • What is the size of Olix Pharmaceuticals?

    Olix Pharmaceuticals has 67 total employees.

  • What industry is Olix Pharmaceuticals in?

    Olix Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Olix Pharmaceuticals a private or public company?

    Olix Pharmaceuticals is a Public company.

  • What is Olix Pharmaceuticals’s stock symbol?

    The ticker symbol for Olix Pharmaceuticals is 226950.

  • What is the current stock price of Olix Pharmaceuticals?

    As of 16-Nov-2026 the stock price of Olix Pharmaceuticals is $56.08.

  • What is the current market cap of Olix Pharmaceuticals?

    The current market capitalization of Olix Pharmaceuticals is $1.28B.

  • What is Olix Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Olix Pharmaceuticals is $9.4M.

  • Who are Olix Pharmaceuticals’s competitors?

    Redx Pharma, Fate Therapeutics, Beam Therapeutics, Immunocore Holdings, and Sarepta Therapeutics are some of the 78 competitors of Olix Pharmaceuticals.

  • What is Olix Pharmaceuticals’s annual earnings per share (EPS)?

    Olix Pharmaceuticals’s EPS for 12 months was -$0.39.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process